Exploring why some brains are more resilient to the impact of Alzheimer’s disease could lead to improved diagnoses, treatment and prevention.

Advanced proteomic analysis tools dig deep into human blood plasma to understand the molecular nature of advanced alcoholic disease.

A detailed snapshot of proteins by PNNL scientists marks a big step toward a diagnostic blood test for a deadly form of liver disease.

Findings show method to better prepare human lung tissue for study; it represents the latest mass spectrometry-based omics advances.

New research findings published in Science Advances (November 2022), help explain the progression of Alzheimer-related dementia in each patient. The findings outline a biological classification system that predicts disease severity.

PNNL chemist Ying Zhu was honored as one of the top 40 researchers under the age of 40 in analytical science by The Analytical Scientist.

The Washington State Academy of Sciences added six people from PNNL to its 2022 class of inductees.

Researchers use machine learning to speed up the analysis of aerosol datasets from mass spectrometry.

PNNL scientists have developed a new mass spectrometry method for in-depth analysis of proteins in individual cells.

Data from increasingly complex mass spectrometry instruments met with adaptable data analysis solution.

Proteomics revealed molecular mechanisms by which the drug Verapamil could prolong beta cell function in early-onset type 1 diabetes patients.

Study highlights microbiome’s role in regulating xenobiotic metabolism.

Mowei Zhou, a chemist with the Environmental Molecular Sciences Laboratory, is speaking at the ACS spring conference on his latest protein discoveries for a plant that could transform biofuels production.

Development of a one-meter path length miniature ion mobility spectrometer based on multilevel structures for lossless ion manipulations.

Governor Inslee announced the appointment of Karin Rodland to the Board of Directors of the Andy Hill Cancer Research Endowment Fund.

Studying MERS-CoV may lead to better treatments for a host of respiratory illnesses, including the many variants of COVID-19.

PNNL scientists are protecting first responders and others by expanding what’s known about fentanyl, the driver of the opioid epidemic.

Researchers characterize protein signatures that indicate Acute Kidney Injury in COVID-19 patients.

In adjoining Energy Sciences Center laboratories, researchers develop better energy storage devices by understanding the fundamental reactions that form interfaces.

PNNL scientists publish paper and host workshops to share threat-agnostic vision for biodefense.